Saturday - April 11, 2026

Category Archives: Pharmaceuticals & Biotech

UK Supplier Syntech Peptides Enters Growing £1 Billion Research Peptide Market with Rigorous Third-Party Verification Programme

As demand for synthetic peptide compounds in British academic and biotech laboratories reaches record levels, Syntech Peptides launches with a supply model built around independent laboratory verification, domestic cold-chain logistics, and full documentation transparency — addressing a gap that researchers … Continue reading →

K-38 Consulting Releases Healthcare CFO Services Case Study Showcasing Measurable Financial Transformation for Medical Practices

Healthcare CFO Services Raleigh, NC – April 10th, 2026 – K-38 Consulting, a leading provider of outsourced CFO and financial advisory services, announces the release of a new healthcare CFO services case study that demonstrates how strategic financial leadership can unlock … Continue reading →

Undervalued OTC Stocks Radar: ADMQ, ADIA, RDTCF, BFGFF, ROKRF Gaining Investor Attention in 2026

A new wave of undervalued OTC and small-cap stocks is beginning to surface across sectors including manufacturing, biotech, mining, and energy, as investors search for early-stage opportunities with real catalysts. Names like ADM Endeavors (OTCQB: ADMQ), Adia Nutrition Inc. (OTCQB: … Continue reading →

Head and Neck Squamous Cell Carcinomas Market: Rapid Increment Driven by Innovation by 2034 – DelveInsight | M.D. Anderson Cancer Center, Sidney Kimmel, Centre hospitalier de, Dana-Farber Cancer

The Key Head and Neck Squamous Cell Carcinomas Companies in the market include – M.D. Anderson Cancer Center, Sidney Kimmel, Centre hospitalier de, Dana-Farber Cancer Institute, Inovio Pharmaceuticals, Hansoh BioMedical R&D Company, Gilead Sciences, Merck Sharp & Dohme LLC, Exelixis, … Continue reading →

Night Vision Disturbances Pipeline 2026: MOA, ROA, FDA-Approved Drugs, and Clinical Trial Progress Assessment by DelveInsight | Opus Genetics, Viatris, Nevakar, Vyluma, Pfizer, Allergan, AbbVie

(Las Vegas, Nevada, United States) As per DelveInsight’s assessment, globally, Night Vision Disturbances pipeline constitutes key companies continuously working towards developing Night Vision Disturbances treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes … Continue reading →

NK Cell Therapy Pipeline 2026: Therapies, MOA Insights, and Key Clinical Trial Updates by DelveInsight | Amgen, ImmunityBio, Dragonfly Therapeutics, Glycostem Therapeutics, Athenex, Artiva Biotherap

(Las Vegas, Nevada, United States) As per DelveInsight’s assessment, globally, NK Cell Therapy pipeline constitutes 140+ key companies continuously working towards developing 160+ Nk Cell Therapy treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and … Continue reading →

Primary Myelofibrosis Pipeline 2026: Therapies Under Investigation, Clinical Trials Milestones, and FDA Approvals by DelveInsight | Galecto Biotech, Lynk Pharma, Samus Therapeutics, Taiga Biotech

(Las Vegas, Nevada, United States) As per DelveInsight’s assessment, globally, Primary Myelofibrosis pipeline constitutes 55+ key companies continuously working towards developing 55+ Primary Myelofibrosis treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes … Continue reading →

Intratumoral Cancer Therapies Market: Expanding Revenue Landscape to 2034 – DelveInsight | Amgen, Daiichi Sankyo, AiViva BioPharma, Lytix Biopharma, Regeneron Pharma, Checkmate Pharma, Replimune

The Key Intratumoral Cancer Therapies Companies in the market include – Amgen, Daiichi Sankyo, AiViva BioPharma, Lytix Biopharma, Regeneron Pharmaceuticals, Checkmate Pharmaceuticals, OncoSec Medical Incorporated, Merck, Istari Oncology, Replimune, Philogen, Sirnaomics, Exicure, Intensity Therapeutics, NanOlogy, Nanobiotix, Immunovative Therapies, DNAtrix, Idera … Continue reading →

Global Obesity Pipeline Surges as 80+ Pharma Players Intensify Clinical Trials, Paving the Way for Next-Gen Weight Loss Therapies | DelveInsight

Obesity Pipelin Leading Obesity Companies include Zealand Pharma, Sciwind Biosciences, Genexine, Sirnaomics, Sparrow Pharmaceuticals, Shionogi, Regor Pharmaceuticals, Innovent Biologics, Pfizer, NodThera Limited, Boehringer Ingelheim, Fractyl Health, TransThera, Clearmind Medicine, PegBio, Biolingus, and others. DelveInsight’s “Obesity Pipeline Insight 2026” report provides … Continue reading →

Myelodysplastic Syndrome Pipeline Surges as 120+ Pharma Players Accelerate Clinical Innovation and Transform Treatment Landscape by 2034 | DelveInsight

Myelodysplastic Syndrome Pipeline Leading Myelodysplastic Syndrome Companies such as Syros Pharmaceuticals, Curis, Ryvu Therapeutics, Chia Tai Tianqing Pharmaceutical Group, Amgen, Sanofi, Forma Therapeutics, Agios Pharmaceuticals, AbbVie, Daiichi Sankyo Company, Geron Corporation, Astex Pharmaceuticals, Jazz Pharmaceuticals, Maxinovel Pty., Ltd., Mabwell (Shanghai) … Continue reading →